Zimmer Biomet Q4 Revenue and EPS Down 15% Amid Surgical Demand Slump

Zimmer Biomet Holdings Inc. (ZBIO) reported fourth-quarter revenue of $1.12B, a 15% decline from the prior-year period, and EPS of $0.54, down 15% year-over-year. The surgical device and implant company attributed the results to softer demand in knee and spine procedures. For the quarter ended January 31, 2026, the company posted a net loss of $145M, compared to a loss of $105M in the same period last year. Management cited macroeconomic pressures and supply chain disruptions as key headwinds.